Red blood cell changes due to cancer and cancer treatments: a narrative review.

IF 3.1 3区医学 Q2 HEMATOLOGY Current Opinion in Hematology Pub Date : 2025-01-10 DOI:10.1097/MOH.0000000000000859

Deirdre Finnigan, Omar I Hajjaj, Maha Othman

{"title":"Red blood cell changes due to cancer and cancer treatments: a narrative review.","authors":"Deirdre Finnigan, Omar I Hajjaj, Maha Othman","doi":"10.1097/MOH.0000000000000859","DOIUrl":null,"url":null,"abstract":"Purpose of review: To date, there is relatively limited research investigating changes in red blood cells (RBCs), particularly qualitative changes, in cancer patients and cancer patients receiving treatment. These changes may be important in better understanding cancer-associated anemia, which is the most prevalent hematological disorder in cancer patients with wide-ranging implications on patient care and quality of life. This review aims to summarize available evidence regarding qualitative and quantitative changes in RBCs in individuals with cancer prior to treatment and in patients undergoing treatment.Recent findings: The most commonly reported changes in RBCs in cancer patients were increased mean corpuscular volume (MCV) and decreased hemoglobin, RBC count, and hematocrit. There were increased lipid peroxidation products and decreased antioxidants. There were increased polyunsaturated fatty acids (PUFAs) and decreased monounsaturated fatty acids (MUFAs) and saturated fatty acids (FAs). Additionally, RBC shape alterations with various atypical morphologies, membrane structure abnormalities, and impaired fluidity were also reported. These and various other reported findings are discussed in depth.Summary: There are several reported quantitative and qualitative RBC changes in individuals with cancer, with some studies exhibiting conflicting results. Further research is needed to solidify the data and to better understand hematological-associated comorbidities in those patients.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Opinion in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MOH.0000000000000859","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: To date, there is relatively limited research investigating changes in red blood cells (RBCs), particularly qualitative changes, in cancer patients and cancer patients receiving treatment. These changes may be important in better understanding cancer-associated anemia, which is the most prevalent hematological disorder in cancer patients with wide-ranging implications on patient care and quality of life. This review aims to summarize available evidence regarding qualitative and quantitative changes in RBCs in individuals with cancer prior to treatment and in patients undergoing treatment.

Recent findings: The most commonly reported changes in RBCs in cancer patients were increased mean corpuscular volume (MCV) and decreased hemoglobin, RBC count, and hematocrit. There were increased lipid peroxidation products and decreased antioxidants. There were increased polyunsaturated fatty acids (PUFAs) and decreased monounsaturated fatty acids (MUFAs) and saturated fatty acids (FAs). Additionally, RBC shape alterations with various atypical morphologies, membrane structure abnormalities, and impaired fluidity were also reported. These and various other reported findings are discussed in depth.

Summary: There are several reported quantitative and qualitative RBC changes in individuals with cancer, with some studies exhibiting conflicting results. Further research is needed to solidify the data and to better understand hematological-associated comorbidities in those patients.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

癌症和癌症治疗引起的红细胞变化：叙述性回顾。

综述目的：迄今为止，关于癌症患者和接受治疗的癌症患者红细胞（rbc）变化，特别是质变的研究相对有限。这些变化可能对更好地理解癌症相关性贫血很重要，癌症相关性贫血是癌症患者中最常见的血液系统疾病，对患者的护理和生活质量有广泛的影响。本综述旨在总结癌症患者治疗前和治疗中红细胞定性和定量变化的现有证据。最近发现：在癌症患者中最常见的红细胞变化是平均红细胞体积（MCV）增加，血红蛋白、红细胞计数和红细胞压积降低。脂质过氧化产物增加，抗氧化剂减少。多不饱和脂肪酸（PUFAs）增加，单不饱和脂肪酸（MUFAs）和饱和脂肪酸（FAs）减少。此外，RBC形态改变伴有各种非典型形态、膜结构异常和流动性受损也有报道。这些和各种其他报告的发现进行了深入的讨论。总结：有几篇关于癌症患者红细胞定量和定性变化的报道，一些研究显示出相互矛盾的结果。需要进一步的研究来巩固这些数据，并更好地了解这些患者的血液学相关合并症。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current Opinion in Hematology 医学-血液学

CiteScore

6.60

自引率

3.10%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Opinion in Hematology is an easy-to-digest bimonthly journal covering the most interesting and important advances in the field of hematology. Its hand-picked selection of editors ensure the highest quality selection of unbiased review articles on themes from nine key subject areas, including myeloid biology, Vascular biology, hematopoiesis and erythroid system and its diseases.